351. Novel BACE1 inhibitors with a non-acidic heterocycle at the P1' position.
- Author
-
Suzuki K, Hamada Y, Nguyen JT, and Kiso Y
- Subjects
- Amyloid Precursor Protein Secretases genetics, Amyloid Precursor Protein Secretases metabolism, Aspartic Acid Endopeptidases genetics, Aspartic Acid Endopeptidases metabolism, Benzamides chemical synthesis, Benzamides metabolism, Heterocyclic Compounds chemical synthesis, Heterocyclic Compounds metabolism, Humans, Hydrogen Bonding, Protease Inhibitors chemical synthesis, Protease Inhibitors metabolism, Protein Binding, Quantitative Structure-Activity Relationship, Recombinant Proteins biosynthesis, Recombinant Proteins chemistry, Recombinant Proteins genetics, Thiadiazoles chemical synthesis, Thiadiazoles metabolism, Amyloid Precursor Protein Secretases antagonists & inhibitors, Aspartic Acid Endopeptidases antagonists & inhibitors, Benzamides chemistry, Heterocyclic Compounds chemistry, Protease Inhibitors chemistry, Thiadiazoles chemistry
- Abstract
We have reported potent peptidic and non-peptidic BACE1 inhibitors with a hydroxymethylcarbonyl (HMC) isostere as a substrate transition-state mimic. However, our potent inhibitors possess a tetrazole ring at the P1' position. It is desirable that central nervous system (CNS) drugs do not possess an acidic moiety. In this study, we synthesized non-acidic BACE1 inhibitors with heterocyclic derivatives at the P1' position. KMI-1764 (27) exhibited potent inhibitory activity (IC50=27nM). Interestingly, these non-acidic inhibitors tended to follow the quantitative structure-activity relationship (QSAR) equation and interacted with BACE1-Arg235 in the binding model., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF